Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Jazz Pharmaceuticals plc - Ordinary Shares
(NQ:
JAZZ
)
203.42
+5.59 (+2.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
634,763
Open
198.13
Bid (Size)
197.00 (100)
Ask (Size)
205.08 (100)
Prev. Close
197.83
Today's Range
197.68 - 204.13
52wk Range
97.50 - 204.13
Shares Outstanding
62,311,104
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
April 06, 2026
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...
Via
MarketMinute
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
March 31, 2026
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Performance
YTD
+17.5%
+17.5%
1 Month
+12.7%
+12.7%
3 Month
+20.1%
+20.1%
6 Month
+49.5%
+49.5%
1 Year
+97.9%
+97.9%
More News
Read More
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Beats Q4 Estimates but 2026 Guidance Tempers Gains
↗
February 24, 2026
Via
Chartmill
1 Value Stock to Research Further and 2 We Ignore
March 18, 2026
Via
StockStory
3 Healthcare Stocks Walking a Fine Line
March 13, 2026
Via
StockStory
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript
↗
March 02, 2026
Via
The Motley Fool
Topics
Earnings
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
February 25, 2026
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales
February 24, 2026
Via
StockStory
Jazz Pharmaceuticals Earnings: What To Look For From JAZZ
February 22, 2026
Via
StockStory
Topics
Artificial Intelligence
Government
World Trade
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
February 15, 2026
Via
StockStory
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid
February 10, 2026
Via
StockStory
3 Cash-Producing Stocks We Think Twice About
February 05, 2026
Via
StockStory
$100 Million Exit: Why One Fund Walked Away From a Chinese E-Commerce Stock Up 24%
↗
January 29, 2026
Via
The Motley Fool
Topics
Economy
This Bank Stock Just Saw a $24 Million Fund Sale, but Here's Why It's Still a Top Holding
↗
January 29, 2026
Via
The Motley Fool
Topics
Credit Cards
ETFs
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?
↗
January 27, 2026
Via
The Motley Fool
Topics
Initial Public Offering
Intellectual Property
3 of Wall Street’s Favorite Stocks We Think Twice About
January 26, 2026
Via
StockStory
3 Small-Cap Stocks That Fall Short
January 12, 2026
Via
StockStory
Topics
Electric Vehicles
Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ)
December 28, 2025
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Mid-Cap Stocks with Warning Signs
December 22, 2025
Via
StockStory
3 Reasons JAZZ is Risky and 1 Stock to Buy Instead
December 17, 2025
Via
StockStory
Topics
Bankruptcy
3 Value Stocks We’re Skeptical Of
December 11, 2025
Via
StockStory
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?
↗
December 09, 2025
Via
The Motley Fool
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?
↗
December 09, 2025
Via
The Motley Fool
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets
↗
December 09, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
3 Healthcare Stocks We’re Skeptical Of
December 02, 2025
Via
StockStory
Topics
Stocks
Frequently Asked Questions
Is Jazz Pharmaceuticals plc - Ordinary Shares publicly traded?
Yes, Jazz Pharmaceuticals plc - Ordinary Shares is publicly traded.
What exchange does Jazz Pharmaceuticals plc - Ordinary Shares trade on?
Jazz Pharmaceuticals plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares?
The ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares is JAZZ on the Nasdaq Stock Market
What is the current price of Jazz Pharmaceuticals plc - Ordinary Shares?
The current price of Jazz Pharmaceuticals plc - Ordinary Shares is 203.42
When was Jazz Pharmaceuticals plc - Ordinary Shares last traded?
The last trade of Jazz Pharmaceuticals plc - Ordinary Shares was at 04/17/26 04:00 PM ET
What is the market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares?
The market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares is 12.68B
How many shares of Jazz Pharmaceuticals plc - Ordinary Shares are outstanding?
Jazz Pharmaceuticals plc - Ordinary Shares has 13B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.